Thursday, December 15, 2022 Daily Archives

Cell Therapy — Supply Chain Discussions

by , , , and

The 2017 approval of Kymriah (tisagenlecleucel) has paved the way for other cell therapy products to reach the patients who need them. Each passing year promises to open the regulatory floodgates to more product approvals, but technical and manufacturing issues continue to keep initially high expectations from being realized. One barrier is supply chain complexity, especially for the subset of autologous cell therapies. This eBook features expert commentary from Be The Match BioTherapies, a company providing more than 50 product…

December 15, 2022

Improving Scalability of AAV and Lentivirus Production: Tailored Transfection Reagents Enable Large-Scale Manufacturing

by

Scientific advances have increased the safety and efficacy of recombinant viral-vector technology for cell and gene therapies. In this special report, we will discuss how tailored transfection reagents improve the scalability of AAV and lentivirus production. We will also focus on the challenges of scaling up viral vector production platforms and the importance of selecting the right transfection reagent for this process to increase the titer and quality of viral production to generate more therapeutic doses per run. Fill out…

December 15, 2022

Inceptor Bio becomes third company to join Ori’s LEAP program

by

Inceptor has joined Ori Biotech’s LEAP program to advance solid tumor cell therapy access and bolster its manufacturing capabilities ahead of clinical trials. Inceptor has been granted pre-commercial access to Ori’s automated cell and gene therapy manufacturing platform and digital capabilities through joining the company’s LightSpeed Early Access Program (LEAP). Financial details of the deal have not been disclosed but it is confirmed that Inceptor will use Ori’s manufacturing platform technology to produce its chimeric antigen receptor (CAR) M, T,…

December 15, 2022